Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
INCY 
Incyte Corporation (INCY)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: INCY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -4.15% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.18B USD | Price to earnings Ratio 760.22 | 1Y Target Price 79.38 |
Price to earnings Ratio 760.22 | 1Y Target Price 79.38 | ||
Volume (30-day avg) 2148186 | Beta 0.71 | 52 Weeks Range 50.35 - 83.95 | Updated Date 01/1/2025 |
52 Weeks Range 50.35 - 83.95 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.8% | Operating Margin (TTM) 14.96% |
Management Effectiveness
Return on Assets (TTM) -0.12% | Return on Equity (TTM) 0.8% |
Valuation
Trailing PE 760.22 | Forward PE 11.1 | Enterprise Value 11568171698 | Price to Sales(TTM) 3.26 |
Enterprise Value 11568171698 | Price to Sales(TTM) 3.26 | ||
Enterprise Value to Revenue 2.84 | Enterprise Value to EBITDA 31.71 | Shares Outstanding 192650000 | Shares Floating 160211800 |
Shares Outstanding 192650000 | Shares Floating 160211800 | ||
Percent Insiders 2.04 | Percent Institutions 97.71 |
AI Summary
Incyte Corporation: A Comprehensive Overview
Company Profile
History and Background: Incyte Corporation, founded in 1991, is a global biopharmaceutical company headquartered in Wilmington, Delaware. It focuses on discovering, developing, and commercializing therapies for patients with serious unmet medical needs, primarily in oncology and inflammation. Incyte has experienced significant growth, expanding its portfolio through internal research and strategic acquisitions.
Core Business Areas:
- Oncology: Incyte develops and commercializes targeted therapies for various hematologic and solid tumors. Key products include Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor used for myelofibrosis, polycythemia vera, and graft-versus-host disease; and Iclusig (ponatinib), a BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia.
- Inflammation: Incyte focuses on developing therapies for autoimmune and inflammatory diseases. Key products include Olumiant (baricitinib), a JAK1/JAK2 inhibitor used for rheumatoid arthritis and atopic dermatitis.
Leadership Team and Corporate Structure: Incyte boasts a seasoned leadership team with deep experience in the pharmaceutical industry. Hervé Hoppenot serves as President and CEO, leading the company's overall direction. The executive team includes experienced leaders in research and development, commercial operations, finance, and legal affairs.
Top Products and Market Share
Top Products: Jakafi, Iclusig, and Olumiant are Incyte's top revenue generators. Jakafi, a blockbuster drug, contributed significantly to the company's revenue.
Market Share: Incyte holds a significant market share in the JAK inhibitor market for myelofibrosis and polycythemia vera. However, competition is intensifying with the entry of new players.
Product Performance and Market Reception: Jakafi and Olumiant have received positive reviews from healthcare professionals and patients, demonstrating their efficacy and safety. However, Iclusig has faced safety concerns, impacting its market share.
Total Addressable Market
The global oncology market is estimated to reach $277.3 billion by 2027, while the global autoimmune disease market is projected to reach $170.2 billion by the same year. Incyte operates in a vast and growing market with significant potential.
Financial Performance
Recent Financial Statements: Incyte's recent financial performance has been strong, with consistent revenue and earnings growth. The company reported $2.2 billion in revenue and $1.5 billion in net income for the fiscal year 2022.
Year-over-Year Comparison: Incyte has demonstrated consistent year-over-year growth in revenue, net income, and EPS.
Cash Flow and Balance Sheet: Incyte has a healthy cash flow and a strong balance sheet with low debt levels.
Dividends and Shareholder Returns
Dividend History: Incyte initiated a dividend payout in 2021. The current annual dividend yield is approximately 0.4%.
Shareholder Returns: Incyte has delivered strong shareholder returns over the past 5 and 10 years, exceeding the S&P 500 index performance.
Growth Trajectory
Historical Growth: Incyte has experienced significant historical growth, driven by the commercial success of Jakafi and Olumiant.
Future Projections: Analysts project continued growth for Incyte, driven by new product launches and expanding market opportunities.
Recent Initiatives: Incyte is actively pursuing growth through strategic acquisitions, product development, and expansion into new markets.
Market Dynamics
Industry Trends: The pharmaceutical industry is characterized by rapid technological advancements, increasing competition, and evolving regulatory landscape.
Incyte's Positioning: Incyte is well-positioned within the industry due to its strong product portfolio, experienced leadership team, and focus on innovation.
Competitors
Key Competitors: Key competitors include Bristol Myers Squibb (BMY), Pfizer (PFE), AbbVie (ABBV), and Gilead Sciences (GILD).
Market Share and Comparison: Incyte holds a strong market position in the JAK inhibitor market but faces competition from established players in the oncology and inflammation markets.
Competitive Advantages and Disadvantages: Incyte's key competitive advantages include its innovative product portfolio, strong R&D capabilities, and commercial expertise. However, the company faces challenges from larger competitors with broader product offerings and global reach.
Potential Challenges and Opportunities
Key Challenges: Incyte faces challenges such as maintaining product exclusivity, navigating regulatory hurdles, and managing competitive pressures.
Potential Opportunities: Opportunities include expanding into new markets, developing next-generation therapies, and pursuing strategic partnerships.
Recent Acquisitions
2021:
- MorphoSys AG: Acquired for $1.1 billion to gain access to tafasitamab, a potential blockbuster drug for B-cell non-Hodgkin lymphoma.
2022:
- Calliditas Therapeutics AB: Acquired for $1.3 billion to expand Incyte's portfolio into autoimmune diseases and access to tarpeyomab, a promising drug for immunoglobulin A nephropathy.
These acquisitions align with Incyte's strategy to enhance its product portfolio, expand into new therapeutic areas, and drive future growth.
AI-Based Fundamental Rating
Rating: 8/10
Justification: Incyte demonstrates strong financial performance, a promising product pipeline, and a well-positioned portfolio within the growing oncology and inflammation markets. However, competition remains a significant challenge.
Disclaimer: The information provided is for general knowledge and educational purposes only and does not constitute investment advice. Please consult with a qualified financial professional before making any investment decisions.
Sources:
- Incyte Corporation Investor Relations website
- SEC filings
- Bloomberg
- Reuters
- Evaluate Pharma
- Company press releases
- Financial news articles
Note: This overview is based on publicly available information as of November 2023. Please refer to the company's official website and recent filings for the most up-to-date information.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 1993-11-04 | CEO & Chairman Mr. Herve Hoppenot | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2524 | Website https://www.incyte.com |
Full time employees 2524 | Website https://www.incyte.com | ||
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.